Halozyme – “HyQvia’s Delay – Percolation to Other Drugs in the Pipeline?”
Delay in the approval of HyQvia SC (R, 10% Gammagard liquid + rHuPH20, partnered with Baxter for primary immunodeficiencies, PI, once monthly) in US accentuates the uncertainties around Halozyme’s (HALO) ENHANZE platform. With revised timeline for launch of HyQvia in US, and likely entry of biosimilars and biobetters, there is a commercial risk to HALO products even if it is approved in EU. FDA’s requirement of more studies for HyQvia could delay partnership and development of other un-partnered programs….. For more details, please read our report released on 9th May, 2012 on Halozyme titled “HyQvia’s Delay – Percolation to Other Drugs in the Pipeline?”
COMPANIES MENTIONED
HALOZYME
HALOZYME
